
Enterome raises €10m series-B
Paris-based Enterome Bioscience has raised €10m in a series-B round from existing backers Seventure, Lundbeckfond Ventures and Omnes Capital.
Seventure invested via the Health for Life Capital fund, which launched in December 2013 with a target of €120m. The vehicle focuses on investments in health nutrition in Europe, North America and Asia.
Enterome will use the fresh funding to support R&D efforts.
Seventure and Lundbeckfond initially backed the firm in 2012 in a €5m series-A round. The company raised a €1.5m seed capital fund from Seventure and consulting company INRA Transfert prior to that. Enterome has raised €17.5m to date.
Company
Founded in 2012 and based in Paris, Enterome develops biomarkers and diagnostics for inflammatory bowel diseases and metabolic disorders involving the gut microbiome. The company will later develop therapeutics in the area.
Enterome's technology was initially developed at the INRA (Institut National de la Recherche Agronomique) in Jouy-en-Josas.
People
Isabelle de Cremoux is the CEO of Seventure. Johan Kordel is a senior partner at Lundbeckfond Ventures.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater